Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight

Research output: Contribution to journal › Letter › Research › peer-review

Standard

Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight. / Svane, Maria S.; Johannesen, Helle H.; Hansen, Adam E.; Martinussen, Christoffer; Bojsen-Møller, Kirstine N.; Hansen, Martin Lundsgaard; Deacon, Carolyn F.; Keller, Sune H.; Klausen, Thomas L.; Loft, Annika; Kjaer, Andreas; Löfgren, Johan; Madsbad, Sten; Holst, Jens J.; Wewer Albrechtsen, Nicolai J.

In: International Journal of Obesity, Vol. 46, No. 11, 2022, p. 2058–2062.

Research output: Contribution to journal › Letter › Research › peer-review

Harvard

Svane, MS, Johannesen, HH, Hansen, AE, Martinussen, C, Bojsen-Møller, KN, Hansen, ML, Deacon, CF, Keller, SH, Klausen, TL, Loft, A, Kjaer, A, Löfgren, J, Madsbad, S, Holst, JJ & Wewer Albrechtsen, NJ 2022, 'Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight', International Journal of Obesity, vol. 46, no. 11, pp. 2058–2062. https://doi.org/10.1038/s41366-022-01207-y

APA

Svane, M. S., Johannesen, H. H., Hansen, A. E., Martinussen, C., Bojsen-Møller, K. N., Hansen, M. L., Deacon, C. F., Keller, S. H., Klausen, T. L., Loft, A., Kjaer, A., Löfgren, J., Madsbad, S., Holst, J. J., & Wewer Albrechtsen, N. J. (2022). Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight. International Journal of Obesity, 46(11), 2058–2062. https://doi.org/10.1038/s41366-022-01207-y

Vancouver

Svane MS, Johannesen HH, Hansen AE, Martinussen C, Bojsen-Møller KN, Hansen ML et al. Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight. International Journal of Obesity. 2022;46(11):2058–2062. https://doi.org/10.1038/s41366-022-01207-y

Author

Svane, Maria S. ; Johannesen, Helle H. ; Hansen, Adam E. ; Martinussen, Christoffer ; Bojsen-Møller, Kirstine N. ; Hansen, Martin Lundsgaard ; Deacon, Carolyn F. ; Keller, Sune H. ; Klausen, Thomas L. ; Loft, Annika ; Kjaer, Andreas ; Löfgren, Johan ; Madsbad, Sten ; Holst, Jens J. ; Wewer Albrechtsen, Nicolai J. / Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight. In: International Journal of Obesity. 2022 ; Vol. 46, No. 11. pp. 2058–2062.

Bibtex

@article{4b62518018a643ee950ba83f0209d560,
title = "Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight",
abstract = "We investigated the effect of pharmacologically induced weight loss on markers of glucagon resistance in individuals with overweight during treatment with the glucagon-like peptide-1 receptor agonist liraglutide. We performed an open-label study in 14 men with overweight (age 38 ± 11 years, BMI 32 ± 4 kg/m2) without simultaneously diabetes. Subjects were treated with liraglutide, initiated and titrated with 0.6 mg/day/week to reach the final dose of 3.0 mg/day. Subjects were examined at baseline, during titration (Week 4), after 2 weeks of steady state (Week 6) of final dosing of liraglutide and 3 weeks after discontinuation of liraglutide (follow-up). Study participants lost 3.3 ± 1.9 kg (3%) total body weight during the first 4 weeks of treatment with liraglutide. Simultaneously, liver fat content decreased from 12.4 ± 11.6% to 10.2 ± 11.1%, p = 0.025, whereas fat content in the spleen and subcutaneous tissue was unaltered. Markers of glucagon resistance, including plasma glucagon and the glucagon-alanine-index, also decreased significantly during treatment, but total and individual plasma amino acid concentrations did not. Insulin resistance (HOMA-IR) was unchanged during treatment, whereas insulin clearance increased. Treatment with the GLP-1 receptor analogue liraglutide decreased liver fat content, and simultaneously attenuated glucagon concentrations and the glucagon-alanine index in individuals with overweight without diabetes.",
author = "Svane, {Maria S.} and Johannesen, {Helle H.} and Hansen, {Adam E.} and Christoffer Martinussen and Bojsen-M{\o}ller, {Kirstine N.} and Hansen, {Martin Lundsgaard} and Deacon, {Carolyn F.} and Keller, {Sune H.} and Klausen, {Thomas L.} and Annika Loft and Andreas Kjaer and Johan L{\"o}fgren and Sten Madsbad and Holst, {Jens J.} and {Wewer Albrechtsen}, {Nicolai J.}",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2022",
doi = "10.1038/s41366-022-01207-y",
language = "English",
volume = "46",
pages = "2058–2062",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "nature publishing group",
number = "11",

}

RIS

TY - JOUR

T1 - Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight

AU - Svane, Maria S.

AU - Johannesen, Helle H.

AU - Hansen, Adam E.

AU - Martinussen, Christoffer

AU - Bojsen-Møller, Kirstine N.

AU - Hansen, Martin Lundsgaard

AU - Deacon, Carolyn F.

AU - Keller, Sune H.

AU - Klausen, Thomas L.

AU - Loft, Annika

AU - Kjaer, Andreas

AU - Löfgren, Johan

AU - Madsbad, Sten

AU - Holst, Jens J.

AU - Wewer Albrechtsen, Nicolai J.

N1 - Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2022

Y1 - 2022

N2 - We investigated the effect of pharmacologically induced weight loss on markers of glucagon resistance in individuals with overweight during treatment with the glucagon-like peptide-1 receptor agonist liraglutide. We performed an open-label study in 14 men with overweight (age 38 ± 11 years, BMI 32 ± 4 kg/m2) without simultaneously diabetes. Subjects were treated with liraglutide, initiated and titrated with 0.6 mg/day/week to reach the final dose of 3.0 mg/day. Subjects were examined at baseline, during titration (Week 4), after 2 weeks of steady state (Week 6) of final dosing of liraglutide and 3 weeks after discontinuation of liraglutide (follow-up). Study participants lost 3.3 ± 1.9 kg (3%) total body weight during the first 4 weeks of treatment with liraglutide. Simultaneously, liver fat content decreased from 12.4 ± 11.6% to 10.2 ± 11.1%, p = 0.025, whereas fat content in the spleen and subcutaneous tissue was unaltered. Markers of glucagon resistance, including plasma glucagon and the glucagon-alanine-index, also decreased significantly during treatment, but total and individual plasma amino acid concentrations did not. Insulin resistance (HOMA-IR) was unchanged during treatment, whereas insulin clearance increased. Treatment with the GLP-1 receptor analogue liraglutide decreased liver fat content, and simultaneously attenuated glucagon concentrations and the glucagon-alanine index in individuals with overweight without diabetes.

AB - We investigated the effect of pharmacologically induced weight loss on markers of glucagon resistance in individuals with overweight during treatment with the glucagon-like peptide-1 receptor agonist liraglutide. We performed an open-label study in 14 men with overweight (age 38 ± 11 years, BMI 32 ± 4 kg/m2) without simultaneously diabetes. Subjects were treated with liraglutide, initiated and titrated with 0.6 mg/day/week to reach the final dose of 3.0 mg/day. Subjects were examined at baseline, during titration (Week 4), after 2 weeks of steady state (Week 6) of final dosing of liraglutide and 3 weeks after discontinuation of liraglutide (follow-up). Study participants lost 3.3 ± 1.9 kg (3%) total body weight during the first 4 weeks of treatment with liraglutide. Simultaneously, liver fat content decreased from 12.4 ± 11.6% to 10.2 ± 11.1%, p = 0.025, whereas fat content in the spleen and subcutaneous tissue was unaltered. Markers of glucagon resistance, including plasma glucagon and the glucagon-alanine-index, also decreased significantly during treatment, but total and individual plasma amino acid concentrations did not. Insulin resistance (HOMA-IR) was unchanged during treatment, whereas insulin clearance increased. Treatment with the GLP-1 receptor analogue liraglutide decreased liver fat content, and simultaneously attenuated glucagon concentrations and the glucagon-alanine index in individuals with overweight without diabetes.

U2 - 10.1038/s41366-022-01207-y

DO - 10.1038/s41366-022-01207-y

M3 - Letter

C2 - 35982119

AN - SCOPUS:85136243978

VL - 46

SP - 2058

EP - 2062

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 11

ER -

ID: 318444360